Chronic Ocular Graft Versus Host Disease: An Update and Review

Main Article Content

Jane Bachman Groth
John Conto
Marcelo Pasquini

Keywords

Key Words: dry eye, ocular graft versus host disease (oGVHD), filamentary keratitis, hematopoietic allogeneic stem cell transplant, cytokines

Abstract

An updated comprehensive literature review was completed of chronic ocular graft versus host disease (oGVHD) to identify current and future considerations as to the causes, diagnosis, and treatment of this complication after allogenic hematopoietic cell transplantation (HCT). Graft-versus-host disease involves multiple organ systems, including the eye, and is a leading cause of mortality and morbidity in these patients. This review consisted a comprehensive search of the PubMed, ClinicalTrials.gov and NIH.gov databases.


      oGVHD is a debilitating and potentially sight threatening condition. Commonly involved ocular structures include the cornea, conjunctiva, meibomian glands, eyelids, lacrimal gland and tear film. Identifying and treating the ocular complications at the early stages may improve final outcomes and quality of life in these patients. Aggressive lubrication, preservation of tear film and inflammation control, including minimizing surface scarring, are treatment goals. Co-management with HCT and other pertinent health care providers is critical for early diagnosis and to initiate prompt therapy to minimize the ocular damage. Stepped therapy, including the use of emerging systemic treatments can be useful in the management of oGVHD with stable visual function, quality of life and complication management as goals of treatment.

Downloads

Download data is not yet available.
Abstract 911 | pdf Downloads 11

References

1. Thomas ED, Lochte HL, Jr., Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257(11):491–6.
2. D’Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2017;23(9):1417–21.
3. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975;292(16):832–43.
4. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292(17):895–902.
5. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Bal-domero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol 2015;2(3):e91–100.
6. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015;21(2):266–74.
7. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol 2004;15(6):503–7.
8. Espana EM, Shah S, Santhiago MR, Singh AD. Graft versus host disease: clinical evaluation, diagnosis and management. Graefes Arch Clin Exp Ophthalmol 2013;251(5):1257–66.
9. Munir SZ, Aylward J. A review of ocular graft-versus-host disease. Optom Vis Sci 2017;94(5):545–55.
10. Na KS, Yoo YS, Mok JW, Lee JW, Joo CK. Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2015;50(11):1459–64.
11. Ogawa Y, Kim SK, Dana R, Clayton J, Jain S, Rosen-blatt MI, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep2013;3:3419.
12. Wang JC, Teichman JC, Mustafa M, O’Donnell H, Broady R, Yeung SN. Risk factors for the develop-ment of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. Br J Ophthalmol 2015;99(11):1514–8.
13. Qiu Y, Hong J, Peng R. Manifestation of clinical catego-ries of ocular graft-versus-host disease. J Ophthalmol 2018;2018:6430953.
14. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol 2013;58(3): 233–51.
15. Inamoto Y, Valdes-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Com-mittee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant 2018.
16. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945–56.
17. Rapoport Y, Freeman T, Koyama T, Engelhardt BG, Jagasia M, Savani BN, et al. Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric. Cornea 2017;36(2):258–63.
18. Cocho L, Fernandez I, Calonge M, Martinez V, Gonzalez-Garcia MJ, Caballero D, et al. Biomark-ers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model. Investigat Ophthalmol Vis Sci 2016;57(2): 746–58.
19. Inamoto Y, Sun YC, Flowers ME, Carpenter PA, Martin PJ, Li P, et al. Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant 2015;21(11):2002–7.
20. Riemens A, Stoyanova E, Rothova A, Kuiper J. Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. Mol Vis 2012;18:797–802.
21. Schargus M, Meyer-ter-Vehn T, Menrath J, Grigoleit GU, Geerling G. Correlation Between Tear Film Os-molarity and the Disease Score of the International Chronic Ocular Graft-Versus-Host-Disease Consensus Group in Hematopoietic Stem Cell Transplantation Patients. Cornea 2015;34(8):911–6.
22. Mathe G, Schwarzenberg L, Amiel JL, Schneider M, Cattan A, Schlumberger JR, et al. Immunogenetic and immunological problems of allogeneic hae-mopoietic radio-chimaeras in man. Scand J Haematol 1967;4(3):193–216.
23. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341(1):14–21.
24. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flow-ers ME, Cutler CS, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011;117(24):6714–20.
25. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119(1):296–307.
26. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001;98(7):2043–51.
27. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214–9.
28. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80(12): 2964–8.
29. Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med 2017;377(26):2565–79.
30. Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015;21(7):1167–87.
31. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015;21(3):389–401.e1.
32. Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 2015;21(6):984–99.
33. Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant 2015;21(8): 1343–59.
34. Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, et al. National Institutes of Health Con-sensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant 2015;21(5):780–92.
35. Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. NIH Consensus develop-ment project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015;21(4):589–603.
36. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood 2017;129(1):30–7.
37. Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016;22(3):449–55.
38. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011;118(15): 4242–9.
39. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017;35(11):1154–61.
40. Pathak M, Diep PP, Lai X, Brinch L, Ruud E, Drol-sum L. Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation with-out total body irradiation. Bone Marrow Transplant 2018;53(7):863–72.
41. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological ma-lignancies: a review. Springer Semin Immunopathol 2004;26(1–2):71–94.
42. Bolanos-Meade J, Reshef R, Fraser R, Fei M, Ab-hyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maravi-roc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 2019;6(3):e132–e43.
43. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 2008;42 Suppl 1:S66–S9.
44. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015;125(4):606–15.
45. Nakasone H, Sahaf B, Miklos DB. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. Int J Hematol 2015;101(5):438–51.
46. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15(9):1005–13.
47. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009;90(2):253–60.
48. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9(8):505–11.
49. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40(3):273–7.
50. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 2017;130(21):2243–50.
51. Rahmat LT, Logan AC. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Drugs of Today (Barcelona, Spain : 1998). 2018;54(5):305–13.
52. Schroeder MA, Choi J, Staser K, DiPersio JF. The Role of Janus Kinase signaling in graft-versus-host disease and graft versus leukemia. Biol Blood Marrow Transplant 2018;24(6):1125–34.
53. Ferreira AM, Pontes da Silva CA, Pereira AD, Szor RS, Medeiros da Fonseca ARB, Serpa MG, et al. Rux-olitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. Bone Marrow Transplant 2018;53(4):503–6.
54. Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, et al. Ruxolitinib: a steroid spar-ing agent in chronic graft-versus-host disease. Bone Marrow Transplant 2018;53(7):826–31.
55. Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E, et al. Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018.
56. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015;29(10):2062–8.
57. Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy 2018;10(5):391–402.
58. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haema-tologica 2015;100(4):479–88.
59. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, et al. A multicenter prospective phase 2 randomized study of extracorporeal photo-pheresis for treatment of chronic graft-versus-host disease. Blood 2008;112(7):2667–74.
60. Richet C, Huynh A, Dimeglio C, Borel C, Lepage B, Boulinguez S, et al. Extracorporeal photopheresis: an efficacious and well-tolerated treatment for cutaneous and oral mucosal chronic graft-versus-host disease. Dermatology (Basel, Switzerland) 2018;234(1–2):23–30.
61. Gandelman JS, Song DJ, Chen H, Engelhardt BG, Chen YB, Clark WB, et al. a prospective trial of ex-tracorporeal photopheresis for chronic graft-versus-host disease reveals significant disease response and no association with frequency of regulatory t cells. Biol Blood Marrow Transplant 2018;24(12):2373–80.
62. Sakellari I, Gavriilaki E, Batsis I, Mallouri D, Pan-teliadou AK, Lazaridou A, et al. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study. J Clin Apheresis 2018;33(6):654–60.
63. Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res 2014;49(2):100–6.
64. Westeneng AC, Hettinga Y, Lokhorst H, Verdonck L, van Dorp S, Rothova A. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea 2010;29(7):758–63.
65. Koch KR, Joussen AM, Huber KK. Ocular involve-ment in chronic graft-versus-host disease: thera-peutic approaches to complicated courses. Cornea 2011;30(1):107–13.
66. Hessen M, Akpek EK. Ocular graft-versus-host disease. Curr Opin Allergy Clin Immunol 2012;12(5):540–7.
67. Inamoto Y, Valdes-Sanz N, Ogawa Y, Alves M, Ber-chicci L, Galvin J, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: Ex-
pert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone
Marrow Transplant 2018.
68. Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green
WR, Santos GW. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983;90(1):4–13.
69. Bray LC, Carey PJ, Proctor SJ, Evans RG, Hamilton PJ. Ocular complications of bone marrow transplanta-tion. Br J Ophthalmol 1991;75(10):611–4.
70. Hirst LW, Jabs DA, Tutschka PJ, Green WR, Santos GW. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol (Chicago, Ill : 1960) 1983;101(4):580–4.
71. Johnson DA, Jabs DA. The ocular manifestations of graft-versus-host disease. Int Ophthalmol Clin 1997;37(2):119–33.
72. Kim SK. Ocular graft vs. host disease. The ocular surface. 2005;3(4 Suppl):S177–9.
73. Kim SK. Update on ocular graft versus host disease. Curr Opin Ophthalmol 2006;17(4):344–8.
74. Lin X, Cavanagh HD. Ocular manifestations of graft-versus-host disease: 10 years’ experience. Clin Ophthalmol (Auckland, NZ) 2015;9:1209–13.
75. Nassiri N, Eslani M, Panahi N, Mehravaran S, Ziaei A, Djalilian AR. Ocular graft versus host disease following allogeneic stem cell transplantation: a review of cur-rent knowledge and recommendations. J Ophthalmic Vis Res 2013;8(4):351–8.
76. Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, et al. Prevalence and risk factors as-sociated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant 2012;47(11):1470–3.
77. Kamoi M, Ogawa Y, Uchino M, Tatematsu Y, Mori T, Okamoto S, et al. Donor-recipient gender difference affects severity of dry eye after hematopoietic stem cell transplantation. Eye (Lond) 2011;25(7):860–5.
78. Uchino M, Ogawa Y, Uchino Y, Mori T, Okamoto S, Tsubota K. Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation. Br J Ophthalmol 2012;96(1): 34–7.
79. Berchicci L, Rabiolo A, Marchese A, Iuliano L, Gigliotti C, Miserocchi E, et al. Ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in an Italian referral center. Ocul Surf 2018;16(3):314–21.
80. Giannaccare G, Versura P, Bonifazi F, Sessa M, Campos EC. Comparison among different diagnostic criteria for chronic ocular graft-versus-host disease applied with and without pre-transplant ophthalmological examination. Eye (Lond) 2019;33(1):154–60.
81. Giannaccare G, Pellegrini M, Taroni L, Bernabei F, Senni C, Grendele A, et al. Corneal biomechanical alterations in patients with chronic ocular Graft Versus-Host Disease. PloS One 2019;14(4):e0213117.
82. Arafat SN, Robert MC, Abud T, Spurr-Michaud S, Amparo F, Dohlman CH, et al. Elevated neutrophil elastase in tears of ocular graft-versus-host disease patients. Am J Ophthalmol 2017;176:46–52.
83. An S, Raju I, Surenkhuu B, Kwon JE, Gulati S, Kara-man M, et al. Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. Ocul Surf 2019;17(3):589–614.
84. Shimizu E, Aketa N, Yazu H, Uchino M, Kamoi M, Sato Y, et al. Corneal higher-order aberrations in eyes with chronic ocular graft-versus-host disease. Ocul Surf 2019.
85. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Clas-sification Report. Ocular Surface 2017;15(3):276–83.
86. Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999;83(10): 1125–30.
87. Townley JR, Dana R, Jacobs DS. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment. Semin Ophthalmol 2011;26(4–5):251–60.
88. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2017;23(2):211–34.
89. Ogawa Y, Kuwana M, Yamazaki K, Mashima Y, Yamada M, Mori T, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Investigat Ophthalmol Visual Sci 2003;44(5):1888–96.
90. Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Na-kamura Y, Ishida S, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Investigat Ophthalmol Vis Sci 2001;42(1):111–9.
91. Kheirkhah A, Coco G, Satitpitakul V, Dana R. Subtarsal fibrosis is associated with ocular surface epitheliopathy in graft-versus-host disease. Am J Ophthalmol 2018;189:102–10.
92. Kusne Y, Temkit M, Khera N, Patel DR, Shen JF. Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease. Ocular Surface 2017;15(4):784–8.
93. He J, Yamane M, Shibata S, Fukui M, Shimizu E, Yano T, et al. Ocular surface and tear film characteristics in a sclerodermatous chronic graft-versus-host disease mouse model. Cornea 2018;37(4):486–94.
94. Perez RL, Perez-Simon JA, Caballero-Velazquez T, Flores T, Carrancio S, Herrero C, et al. Limbus dam-age in ocular graft-versus-host disease. Biol Blood Marrow Transplant 2011;17(2):270–3.
95. Tepelus TC, Chiu GB, Maram J, Huang J, Chopra V, Sadda SR, et al. Corneal features in ocular graft-versus-host disease by in vivo confocal microscopy. Graefes Arch Clin Exp Ophthalmol 2017;255(12):2389–97.
96. He J, Ogawa Y, Mukai S, Saijo-Ban Y, Kamoi M, Uchino M, et al. In vivo confocal microscopy evaluation of ocular surface with graft-versus-host disease-related dry eye disease. Sci Rep 2017;7(1):10720.
97. Berchicci L, Iuliano L, Miserocchi E, Bandello F, Modorati G. Tear osmolarity in ocular graft-versus-host disease. Cornea 2014;33(12):1252–6.
98. Sambursky R, Davitt WF, 3rd, Latkany R, Tauber S, Starr C, Friedberg M, et al. Sensitivity and specific-ity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 2013;131(1):24–8.
99. Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. Ophthalmol 2016;123(11):2300–8.
100. West RH, Szer J, Pedersen JS. Ocular surface and lacrimal disturbances in chronic graft-versus-host disease: the role of conjunctival biopsy. Aust N Z J Ophthalmol 1991;19(3):187–91.
101. Eberwein P, Issleib S, Bohringer D, Mittelviefhaus H, Schwartzkopff J, Finke J, et al. Conjunctival HLA-DR and CD8 expression detected by impression cytology in ocular graft versus host disease. Mol Vis 2013;19:1492–501.
102. Giannaccare G, Bernabei F, Pellegrini M, Arpinati M, Bonifazi F, Sessa M, et al. Eyelid metrics assess-ment in patients with chronic ocular graft versus-host disease. Ocular Surface. 2018.
103. Choi W, Ha JY, Li Y, Choi JH, Ji YS, Yoon KC. Comparison of the meibomian gland dysfunction in patients with chronic ocular graft-versus-host disease and Sjogren’s syndrome. Int J Ophthalmol 2019;12(3):393–400.
104. Hwang HS, Ha M, Kim HS, Na KS. Longitudinal analysis of meibomian gland dropout in patients with ocular graft-versus-host disease. Ocul Surf 2019;17(3):464–9.
105. Giannaccare G, Bonifazi F, Sessa M, Fresina M, Arpinati M, Bandini G, et al. Dry eye disease is already present in hematological patients before hematopoietic stem cell transplantation. Cornea. 2016;35(5):638–43.
106. Cocho L, Fernandez I, Calonge M, Sainz de la Maza M, Rovira M, Stern ME, et al. Prehematopoietic stem cell transplantation tear cytokines as potential susceptibility biomarkers for ocular chronic graft-versus-host disease. Investigat Ophthalmol Vis Sci 2017;58(11):4836–46.
107. Saboo US, Amparo F, Abud TB, Schaumberg DA, Dana R. Vision-Related Quality of life in patients with ocular graft-versus-host disease. Ophthalmol 2015;122(8):1669–74.
108. Riemens A, Te Boome LC, Kalinina Ayuso V, Kuiper JJ, Imhof SM, Lokhorst HM, et al. Impact of ocular graft-versus-host disease on visual quality of life in patients after allogeneic stem cell transplantation: questionnaire study. Acta Ophthalmol 2014;92(1):82–7.
109. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol (Chicago, Ill : 1960). 2001;119(7):1050–8.
110. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocular Surface. 2005;3(4):203–11.
111. Lemp MA. Report of the National Eye Institute/ Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995;21(4):221–32.
112. Hayashi T, Ishioka M, Ito N, Kato Y, Nakagawa H, Hatano H, et al. Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease. Clin Ophthalmol (Auckland, NZ). 2008;2(2):457–9.
113. Kerty E, Vigander K, Flage T, Brinch L. Ocular findings in allogeneic stem cell transplantation without total body irradiation. Ophthalmology 1999;106(7):1334–8.
114. Leite SC, de Castro RS, Alves M, Cunha DA, Correa ME, da Silveira LA, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Trans-plant 2006;38(3):223–7.
115. Blecha C, Wolff D, Holler B, Holler E, Weber D, Vogt R, et al. Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD. Ann Hematol 2016;95(3):493–9.
116. Giannaccare G, Versura P, Bonifazi F, Sessa M, Campos EC. Comparison among different diagnostic criteria for chronic ocular graft-versus-host disease applied with and without pre-transplant ophthalmological examination. Eye (Lond) 2018.
117. Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012;119(3):487–93.
118. Perez VL, Barsam A, Duffort S, Urbieta M, Barreras H, Lightbourn C, et al. Novel scoring criteria for the evaluation of ocular graft-versus-host disease in a preclinical allogeneic hematopoietic stem cell transplantation animal model. Biol Blood Marrow Transplant 2016;22(10):1765–72.
119. Cantu-Rodriguez OG, Vazquez-Mellado A, Gonzalez-Trevino JL, Martinez-Garza DM, Gomez-De Leon A, Hawing-Zarate JA, et al. Cyclosporine A for the prevention of ocular graft versus host disease in al-logeneic hematopoietic stem cell transplant recipients is safe and feasible. Acta Haematol 2019:1–7.
120. Burling-Phillips L MJ, Rapuano CJ, Udell IJ. Topical NSAIDs: Best Practice for Safe Use. EyeNet. 2013.
121. Lelli GJ, Jr., Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI. Ophthalmic cyclosporine use in ocular
GVHD. Cornea 2006;25(6):635–8.
122. Rao SN, Rao RD. Efficacy of topical cyclosporine
0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 2006;25(6):674–8.
123. Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 2008;41(3):293–302.
124. Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea 2010;29(12):1392–6.
125. Sanz-Marco E, Udaondo P, Garcia-Delpech S, Vazquez A, Diaz-Llopis M. Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops. J Ocul Pharmacol Ther 2013;29(8):776–83.
126. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009;28(10):1091–6.
127. Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. J Ocul Pharmacol Ther 2017;33(2):66–72.
128. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Translational Vis Sci Technol 2015;4(3):1.
129. Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, et al. Lifitegrast for the treatment of dry eye disease: results of a phase iii, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology 2017;124(1):53–60.
130. Lollett IV, Galor A. Dry eye syndrome: developments and lifitegrast in perspective. Clinical Ophthalmol (Auckland, NZ). 2018;12:125–39.
131. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocular Surface 2016;14(2):207–15.
132. Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol (Auckland, NZ). 2016;10:1083–94.
133. Chhabra S, Jerkins JH, Conto JE, Hari PN, Zellner K, Shah NN, et al. Topical Lifitegrast 5% for treatment of ocular chronic graft-versus-host disease. 2019.
134. Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea 2012;31(3):299–310.
135. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004;33(10):1031–5.
136. Abud TB, Amparo F, Saboo US, Di Zazzo A, Dohl-man TH, Ciolino JB, et al. A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease. Ophthalmology 2016;123(7):1449–57.
137. Jung JW, Lee YJ, Yoon SC, Kim TI, Kim EK, Seo KY. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol 2015;159(3):519–27 e1.
138. Sabti S, Halter JP, Braun Frankl BC, Goldblum D. Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. Bone Marrow Transplant 2012;47(7):981–4.
139. Tailor R, Gupta A, Herrick A, Kwartz J. Ocular manifestations of scleroderma. Surv Ophthalmol 2009;54(2):292–304.
140. Anitua E, Muruzabal F, de la Fuente M, Riestra A, Merayo-Lloves J, Orive G. PRGF exerts more potent proliferative and anti-inflammatory effects than au-tologous serum on a cell culture inflammatory model. Experiment Eye Res 2016;151:115–21.
141. Azari AA, Karadag R, Kanavi MR, Nehls S, Barney N, Kim K, et al. Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease. Cutan Ocul Toxicol 2017;36(2):152–6.
142. Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 2007;26(7):861–3.
143. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000;25(10):1101–3.
144. Tahmaz V, Gehlsen U, Sauerbier L, Holtick U, Engel L, Radojska S, et al. Treatment of severe chronic ocular graft-versus-host disease using 100% autolo-gous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br J Ophthalmol 2017;101(3):322–6.
145. Zallio F, Mazzucco L, Monaco F, Astori MR, Passera R, Drago G, et al. A single-center pilot prospective study of topical application of platelet-derived eye drops for patients with ocular chronic graft-versus-host disease. Biol Blood Marrow Transplant 2016;22(9): 1664–70.
146. Tunay ZO, Ozdemir O, Acar D, Gul E, Akbay S. Successful treatment of ligneous conjunctivitis with topical fresh frozen plasma in an infant. Arq Bras Oftalmol 2015;78(5):318–9.
147. Giannaccare G, Versura P, Buzzi M, Primavera L, Pel-legrini M, Campos EC. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci 2017;56(4):595–604.
148. Quinto GG, Campos M, Behrens A. Autologous se-rum for ocular surface diseases. Arq Bras Oftalmol 2008;71(6 Suppl):47–54.
149. Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clinical Ophthalmol (Auckland, NZ) 2018;12:1105–12.
150. Chahal HS, Estrada M, Sindt CW, Boehme JA, Greiner MA, Nerad JA, et al. Scleral contact lenses in an academic oculoplastics clinic: epidemiology and emerging considerations. Ophthalm Plastic Reconstruct Surg 2017.
151. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007;26(10):1195–9.
152. Nguyen MTB, Thakrar V, Chan CC. EyePrintPRO therapeutic scleral contact lens: indications and outcomes. Canadian journal of ophthalmology J canadien d’ophtalmologie 2018;53(1):66–70.
153. Schornack MM, Baratz KH, Patel SV, Maguire LJ. Jupiter scleral lenses in the management of chronic graft versus host disease. Eye Contact Lens 2008;34(6):302–5.
154. Stoyanova EI, Otten HM, Wisse R, Rothova A, Riemens A. Bandage and scleral contact lenses for ocular graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Acta Oph-thalmol 2015;93(7):e604.
155. Chugh JP, Jain P, Sen R. Comparative analysis of fresh and dry preserved amniotic membrane trans-plantation in partial limbal stem cell deficiency. Int Ophthalmol 2015;35(3):347–55.
156. Peric Z, Skegro I, Durakovic N, Desnica L, Pulanic D, Serventi-Seiwerth R, et al. Amniotic membrane transplantation-a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease. Bone Marrow Transplant 2018;53(11):1466–9.
157. Turkoglu E, Celik E, Alagoz G. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol 2014;29(3):119–26.
158. Westekemper H, Scholz SL, Thomasen H, Half-wassen C, Steuhl KP. [Ocular graft versus host disease : Corneal complications]. Ophthalmologe 2017;114(8):697–702.
159. Alio JL, Abad M, Scorsetti DH. Preparation, indi-cations and results of human amniotic membrane transplantation for ocular surface disorders. Exp Rev Med Devices 2005;2(2):153–60.
160. Gomes JA, Romano A, Santos MS, Dua HS. Am-niotic membrane use in ophthalmology. Curr Opin Ophthalmol 2005;16(4):233–40.
161. Rauz S, Saw VP. Serum eye drops, amniotic membrane and limbal epithelial stem cells--tools in the treat-ment of ocular surface disease. Cell Tissue Banking 2010;11(1):13–27.
162. Mohammadpour M, Maleki S, Hashemi H, Beheshtne-jad AH. Recurrent corneal perforation due to chronic graft versus host disease; a clinicopathologic report. J Ophthalmic Vis Res 2016;11(1):108–11.
163. IVIG-eye Drops Treatment for Dry Eye Disease [Internet]. 2019 [cited May 1 [Cited 2019 Sept25]].
164. Topical Fibrinogen-Depleted Human Plately Lysate in Patients With Dry Eye Secondary to Graft vs. Host
Disease [Internet]. 2018 [cited 2019 Apr 18].
165. rhDNase Eye Drops in Patients with Ocular GRaft-
Vs.-Host Disease [Internet]. 2016 [cited 2019, Apr 17]. Available from: ClinicalTrials.gov.
166. Sosne G DS, Chaesik K. Thymosin B significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 2015;34(5):491–6.
167. Study for the Treatment of Ocular Chronic Graft-Versus-Host-Disease (GVHD) With Amniotic Fluid Eye Drops (AFED) [Internet]. 2020 [cited 2019 Dec 5]. Available from: ClinicalTrials.gov/ct2/show/ NCT03298815?trial=2.
168. Treatment Sfaety and Efficacay of Pro-ocular(TM) 1% for Chronic Ocular Graft Following Allogeneic HSCT [Internet]. 2019 [cited 2019 Jun 28]. Available from: ClinicalTrials.gov/ct2show/NCT03990051?trial=1.
169. Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease (oGVHD) [Internet]. 2018 [cited 2019 Nov 8]. Available from: ClinicalTrials.gov/ct2/NCT03591874?trial=18.
170. Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders [Internet]. 2018 [cited 2018 Nov 6]. Available from: ClinicalTrials.gov/ct2/ show/NCT03731624?trial=21.
171. Pishnamaz MR, Jafarzadehpour E, Pishnamaz R. Regulatory T cells and ocular graft versus host disease: a novel treatment approach. Med Hypothesis Discov Innov Ophthalmol 2018;7(3):119–21.
172. Shamloo K, Barbarino A, Alfuraih S, Sharma A. Graft versus host disease-associated dry eye: role of ocular surface mucins and the effect of rebamipide, a mucin secretagogue. Invest Ophthalmol Vis Sci 2019;60(14):4511–9.
173. Fukui M, Ogawa Y, Mukai S, Kamoi M, Asato T, Kawakami Y, et al. Reduced expression of VAMP8 in lacrimal gland affected by chronic graft-versus-host disease. J Ophthalmol 2017;2017:1639012.